Recent Advances for Anti-Obesity Agents / 임상당뇨병
Journal of Korean Diabetes
;
: 260-268, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-726853
ABSTRACT
Obesity is one of the most significant risk factor for diabetes, cardiovascular disease, malignancy and other chronic diseases. The obesity and its associated conditions is one of the most urgent health concerns worldwide. Lifestyle modifications comprising diet modification, exercise, and behavior therapy are basic to the treatment for obesity. However, it has become apparent that lifestyle modifications alone will not be enough for many patients with obesity. Therefore, apractical approach includes consideration of pharmacotherapeutic options. Until 2012, orlistat was the only approved medication for long-term obesity management. In 2012, lorcaserin and phentermine/topiramate were approved by the USA Food and Drug Administration as new anti-obesity drugs, and in 2014, two additional medications were added, naltrexone/bupropion and liraglutide. This review discusses the different pharmacotherapeutic options for the treatment of obesity.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
United States Food and Drug Administration
/
Terapia Comportamental
/
Doenças Cardiovasculares
/
Doença Crônica
/
Fatores de Risco
/
Fármacos Antiobesidade
/
Comportamento Alimentar
/
Liraglutida
/
Estilo de Vida
/
Obesidade
Tipo de estudo:
Estudo de etiologia
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS